206 lines
57 KiB
HTML
206 lines
57 KiB
HTML
<!DOCTYPE html>
|
||
<html lang="" xml:lang="" xmlns="http://www.w3.org/1999/xhtml"><head>
|
||
<meta charset="utf-8"/>
|
||
<meta content="pandoc" name="generator"/>
|
||
<meta content="width=device-width, initial-scale=1.0, user-scalable=yes" name="viewport"/>
|
||
<title>06 March, 2022</title>
|
||
<style type="text/css">
|
||
code{white-space: pre-wrap;}
|
||
span.smallcaps{font-variant: small-caps;}
|
||
span.underline{text-decoration: underline;}
|
||
div.column{display: inline-block; vertical-align: top; width: 50%;}
|
||
</style>
|
||
<title>Covid-19 Sentry</title><meta content="width=device-width, initial-scale=1.0" name="viewport"/><link href="styles/simple.css" rel="stylesheet"/><link href="../styles/simple.css" rel="stylesheet"/><link href="https://unpkg.com/aos@2.3.1/dist/aos.css" rel="stylesheet"/><script src="https://unpkg.com/aos@2.3.1/dist/aos.js"></script></head>
|
||
<body>
|
||
<h1 data-aos="fade-down" id="covid-19-sentry">Covid-19 Sentry</h1>
|
||
<h1 data-aos="fade-right" data-aos-anchor-placement="top-bottom" id="contents">Contents</h1>
|
||
<ul>
|
||
<li><a href="#from-preprints">From Preprints</a></li>
|
||
<li><a href="#from-clinical-trials">From Clinical Trials</a></li>
|
||
<li><a href="#from-pubmed">From PubMed</a></li>
|
||
<li><a href="#from-patent-search">From Patent Search</a></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-preprints">From Preprints</h1>
|
||
<ul>
|
||
<li><strong>Using routine emergency department data for syndromic surveillance of acute respiratory illness in Germany, week 10-2017 and 10-2021</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background: The Coronavirus disease 2019 (COVID-19) pandemic expanded the need for timely information on acute respiratory illness on the population level. Aim: We explored the potential of routine emergency department data for syndromic surveillance of acute respiratory illness in Germany. Methods: We included routine attendance data from emergency departments who continuously transferred data between week 10-2017 and 10-2021, with ICD-10 codes available for >75% of the attendances. Case definitions for acute respiratory illness (ARI), severe ARI (SARI), influenza-like illness (ILI), respiratory syncytial virus disease (RSV) and COVID-19 were based on a combination of ICD-10 codes, and/or chief complaints, sometimes combined with information on hospitalisation and age. Results: We included 1,372,958 attendances from eight emergency departments. The number of attendances dropped in March 2020, increased during summer, and declined again during the resurge of COVID-19 cases in autumn and winter of 2020/2021. A pattern of seasonality of acute respiratory infections could be observed. By using different case definitions (i.e. for ARI, SARI, ILI, RSV) both the annual influenza seasons in the years 2017-2020 and the dynamics of the COVID-19 pandemic in 2020-2021 were apparent. The absence of the 2020/2021 flu season was visible, parallel to the resurge of COVID-19 cases. The percentage SARI among ARI cases peaked in April-May 2020 (17%) and November 2020-January 2021 (14%). Conclusion: Syndromic surveillance using routine emergency department data has the potential to monitor the trends, timing, duration, magnitude and severity of illness caused by respiratory viruses, including both influenza and SARS-CoV-2.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.08.19.21262303v2" target="_blank">Using routine emergency department data for syndromic surveillance of acute respiratory illness in Germany, week 10-2017 and 10-2021</a>
|
||
</div></li>
|
||
<li><strong>Review of COVID-19 in Children Admitted to King Fahad Hospital, Albaha, Saudi Arabia in 2020</strong> -
|
||
<div>
|
||
Background: The coronavirus disease (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified at the end of 2019 in Wuhan City, China and then spread worldwide. Objectives: The study aimed to evaluate COVID-19 symptoms, signs, management, and outcomes in admitted children. Methods: This retrospective cohort study was conducted at King Fahad Hospital, Albaha, Saudi Arabia, which is designated as the center for COVID-19 patients. Data were collected retrospectively between Apr 2020 and Mar 2021. The protocols of health authorities in Saudi Arabia were used for the diagnosis and management of all patients. Results: Positive test results were confirmed in 95 patients. Of these, 44 (46%) were males and 51 (54%) were females. Fever, cough, nasal congestion, sore throat, myalgia, and upper respiratory tract infections were the most common symptoms. The common comorbidities in this cohort were respiratory diseases (19%), type1 diabetes mellitus (16%), followed by obesity (11%), chronic kidney disease (4%), congenital heart diseases (2%), while in (48%) pts no comorbidity factors were reported. Fever was the most frequent symptom, reported in 95% of patients. Multisystem inflammatory syndrome (MIS-C) has been reported in one patient. Guillain-Barre syndrome was reported in one female patient and Kawasaki symptoms in one male patient. No mortality was reported. Conclusion: Most children with COVID-19 presented with mild clinical manifestations and good outcomes. No mortality was reported in this study. Obesity is a serious comorbidity and risk factor for severe diseases.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/u9fmr/" target="_blank">Review of COVID-19 in Children Admitted to King Fahad Hospital, Albaha, Saudi Arabia in 2020</a>
|
||
</div></li>
|
||
<li><strong>Precision recruitment for high-risk participants in a COVID-19 research study</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Studies for developing diagnostics and treatments for infectious diseases usually require observing the onset of infection during the study period. However, when the infection base rate incidence is low, the cohort size required to measure an effect becomes large, and recruitment becomes costly and prolonged. We describe an approach for reducing recruiting time and resources in a COVID-19 study by targeting recruitment to high-risk individuals. Our approach is based on direct and longitudinal connection with research participants and computes individual risk scores from individually permissioned data about socioeconomic and behavioural data, in combination with predicted local prevalence data. When we used these scores to recruit a balanced cohort of participants for a COVID-19 detection study, we obtained a 4- to 7-fold greater COVID-19 infection incidence compared with similar real-world study cohorts.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.03.03.22271504v1" target="_blank">Precision recruitment for high-risk participants in a COVID-19 research study</a>
|
||
</div></li>
|
||
<li><strong>Association between COVID-19 Risk-Mitigation Behaviors and Specific Mental Disorders in Youth</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Importance: Although studies of adults show that pre-existing mental disorders increase risk for COVID-19 infection and severity, there is limited information about this association among youth. Mental disorders in general as well as specific types of disorders may influence their ability to comply with risk-mitigation strategies to reduce COVID-19 infection and transmission. Objective: To examine associations between specific mental disorders and COVID-19 risk-mitigation practices among 314 female and 514 male youth. Design: Youth compliance (rated as Never, Sometimes, Often, or Very often/Always) with risk mitigation was reported by parents on the CoRonavIruS Health Impact Survey (CRISIS) in January 2021. Responses were summarized using factor analysis of risk mitigation, and their associations with lifetime mental disorders (assessed via structured diagnostic interviews) were identified with linear regression analyses (adjusted for covariates). All analyses used R Project for Statistical Computing for Mac (v.4.0.5). Setting: The Healthy Brain Network (HBN) in New York City Participants: 314 female and 514 male youth (ages 5-21) Main Outcome(s) and Measure(s): COVID-19 risk mitigation behaviors among youth Results: A two-factor model was the best-fitting solution. Factor 1 (avoidance behaviors) included avoiding groups, indoor settings, and other peoples homes; avoidance was more likely among youth with any anxiety disorder (p=.01). Factor 2 (hygiene behaviors) included using hand sanitizer, washing hands, and maintaining social distance; practicing hygiene was less likely among youth with ADHD (combined type) (p=.02). Mask wearing, which did not load on either factor, was not associated with any mental health disorder. Conclusion and Relevance: Findings suggest that education and monitoring of risk-mitigation strategies in certain subgroups of youth may reduce risk of exposure to COVID-19 and other contagious diseases. Additionally, they highlight the need for greater attention to vaccine prioritization for individuals with ADHD. Keywords: risk mitigation, COVID-19, youth, CRISIS, anxiety, ADHD
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.03.03.22271787v1" target="_blank">Association between COVID-19 Risk- Mitigation Behaviors and Specific Mental Disorders in Youth</a>
|
||
</div></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Covid-19 Exposure Assessment Tool (CEAT): Easy-to-use tool to quantify exposure based on airflow, group behavior, and infection prevalence in the community</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
The COVID-19 Exposure Assessment Tool (CEAT) allows users to compare respiratory relative risk to SARS-CoV-2 for various scenarios, providing understanding of how combinations of protective measures affect exposure, dose, and risk. CEAT incorporates mechanistic, stochastic and epidemiological factors including the: 1) emission rate of virus, 2) viral aerosol degradation and removal, 3) duration of activity/exposure, 4) inhalation rates, 5) ventilation rates (indoors/outdoors), 6) volume of indoor space, 7) filtration, 8) mask use and effectiveness, 9) distance between people,</p></div></li>
|
||
</ul>
|
||
<ol start="10" type="1">
|
||
<li>group size, 11) current infection rates by variant, 12) prevalence of infection and immunity in the community, 13) vaccination rates of the community, and 14) implementation of COVID-19 testing procedures. Demonstration of CEAT, from published studies of COVID-19 transmission events, shows the model accurately predicts transmission. We also show how health and safety professionals at NASA Ames Research Center used CEAT to manage potential risks posed by SARS-CoV-2 exposures.
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"></p>
|
||
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.03.02.22271806v1" target="_blank">Covid-19 Exposure Assessment Tool (CEAT): Easy-to-use tool to quantify exposure based on airflow, group behavior, and infection prevalence in the community</a>
|
||
</div></li>
|
||
</ol>
|
||
<ul>
|
||
<li><strong>The relationship between BMI and COVID-19: exploring misclassification and selection bias in a two-sample Mendelian randomisation study</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Objective: To use the example of the effect of body mass index (BMI) on COVID-19 susceptibility and severity to illustrate methods to explore potential selection and misclassification bias in Mendelian randomisation (MR) of COVID-19 determinants. Design: Two-sample MR analysis. Setting: Summary statistics from the Genetic Investigation of ANthropometric Traits (GIANT) and COVID-19 Host Genetics Initiative (HGI) consortia. Participants: 681,275 participants in GIANT and more than 2.5 million people from the COVID-19 HGI consortia. Exposure: Genetically instrumented BMI. Main outcome measures: Seven case/control definitions for SARS-CoV-2 infection and COVID-19 severity: very severe respiratory confirmed COVID-19 vs not hospitalised COVID-19 (A1) and vs population (those who were never tested, tested negative or had unknown testing status (A2)); hospitalised COVID-19 vs not hospitalised COVID-19 (B1) and vs population (B2); COVID-19 vs lab/self-reported negative (C1) and vs population (C2); and predicted COVID-19 from self-reported symptoms vs predicted or self-reported non-COVID-19 (D1). Results: With the exception of A1 comparison, genetically higher BMI was associated with higher odds of COVID-19 in all comparison groups, with odds ratios (OR) ranging from 1.11 (95%CI: 0.94, 1.32) for D1 to 1.57 (95%CI: 1.57 (1.39, 1.78) for A2. As a method to assess selection bias, we found no strong evidence of an effect of COVID-19 on BMI in a 9no-relevance9 analysis, in which COVID-19 was considered the exposure, although measured after BMI. We found evidence of genetic correlation between COVID-19 outcomes and potential predictors of selection determined a priori (smoking, education, and income), which could either indicate selection bias or a causal pathway to infection. Results from multivariable MR adjusting for these predictors of selection yielded similar results to the main analysis, suggesting the latter. Conclusions: We have proposed a set of analyses for exploring potential selection and misclassification bias in MR studies of risk factors for SARS-CoV-2 infection and COVID-19 and demonstrated this with an illustrative example. Although selection by socioeconomic position and related traits is present, MR results are not substantially affected by selection/misclassification bias in our example. We recommend the methods we demonstrate, and provide detailed analytic code for their use, are used in MR studies assessing risk factors for COVID-19, and other MR studies where such biases are likely in the available data.
|
||
</p>
|
||
</div>
|
||
<div class="article- link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.03.03.22271836v1" target="_blank">The relationship between BMI and COVID-19: exploring misclassification and selection bias in a two- sample Mendelian randomisation study</a>
|
||
</div></li>
|
||
<li><strong>Request for Immediate Intervention by the Public Health Authorities to Counter the Infodemic Related to the Russian Attack in Ukraine</strong> -
|
||
<div>
|
||
The growing infodemic related to the Russian attack in Ukraine risks creating a similar or even worse scenario than what happened with the COVID-19 pandemic. Based on the evidence from this letter, we suggest that Google Trends be employed by public health authorities to monitor the infodemiological situation.
|
||
</div>
|
||
<div class="article-link article- html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/frjtx/" target="_blank">Request for Immediate Intervention by the Public Health Authorities to Counter the Infodemic Related to the Russian Attack in Ukraine</a>
|
||
</div></li>
|
||
<li><strong>Effect of Yoga on the stress, anxiety, and depression of COVID-19 positive patients. A pre-post quasi randomized study.</strong> -
|
||
<div>
|
||
Background and aim: - Due to the spread of COVID-19 there have been reports of increase in stress, anxiety, and depression across the society, especially so in the affected people, impacting the mental health and well-being. This paper reports a quasi-randomized control study conducted in covid wards of a hospital, to examine the efficacy of add-on yoga intervention in reducing stress, anxiety, and depression in the covid affected patients under quarantine. The oxygen saturation level (SPO2) and heart rate (HR) of the covid affected patients were also measured along with the stress. Experimental procedure: - A total of sixty-two COVID-19 positive patients participated in the study. The participants were randomized into the control group (n=31) which received conventional medical treatment alone and the yoga intervention group (n=31) which additionally received 50 minutes of yoga intervention along with conventional medical treatment. Standardized scales of Hospital Anxiety and Depression Scale (HADS-14), Generalized Anxiety Disorder (GAD-7), Patient Health Questionnaire (PHQ-9) and Perceived Stress Scale (PSS-10) were administered at the beginning as well as at the end of the quarantine period. Results: - A significant decrease in stress, anxiety and depression were observed in the patients who undertook the add-on yoga intervention. Also, improvement in SPO2 and HR levels were observed in the group of patients who were practicing yoga. Conclusion- Findings of this study suggest that add-on Yoga intervention can be an effective add-on practice in reducing stress, anxiety, and depression level of COVID-19 patients.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/2cswy/" target="_blank">Effect of Yoga on the stress, anxiety, and depression of COVID-19 positive patients. A pre-post quasi randomized study.</a>
|
||
</div></li>
|
||
<li><strong>Initial Assessment of SARS-CoV-2 Omicron Variant in Exhaled Breath Aerosol</strong> -
|
||
<div>
|
||
From December 16 through 21 of 2021, we collected exhaled breath aerosol (EBA) from five members of a University campus community infected with SARS-CoV-2 viruses displaying an S-gene target failure when assayed using the TaqPath COVID-19 Real Time PCR Assay (Thermo Scientific).
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://osf.io/mtdx9/" target="_blank">Initial Assessment of SARS-CoV-2 Omicron Variant in Exhaled Breath Aerosol</a>
|
||
</div></li>
|
||
<li><strong>Positive and negative risk-taking in adolescence and early adulthood: A citizen science study during the COVID-19 pandemic</strong> -
|
||
<div>
|
||
Sensation seeking is an important underlying factor of both positive and negative forms of risk-taking during adolescence and early adulthood. However, macro-factors such as the global Covid-19 pandemic may influence sensation seeking opportunities and risk-taking behaviors that are considered negative and positive. Therefore, the primary aim of this study was to examine the associations between sensation seeking and behaviors that are considered positive or negative forms of risk-taking during the Covid-19 pandemic in a sample of adolescents and early adults (N = 660, Mage = 22.91, SD = 3.14). Using citizen science methods, negative risk-taking was defined as taking unaccepted risks, such as falsifying vaccination reports or deliberately contracting Covid-19. Positive risk-taking was defined as taking socially accepted risks, such as balancing between the risk to infect elderly people and the need to socialize with peers. Results showed that participants with higher levels of sensation seeking took more positive and negative Covid-19 related risks. An additional finding was that sensation seeking was positively associated with the experienced need to contribute to society. This indicates that during adolescence and early adulthood, sensation seeking may be a driving factor for both positive (i.e., socially accepted) and negative (i.e., socially unaccepted) risk-taking in the context of a high-stake global pandemic, arguing against a one-direction negative relation between sensation seeking and risk-taking.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://psyarxiv.com/n8g9m/" target="_blank">Positive and negative risk-taking in adolescence and early adulthood: A citizen science study during the COVID-19 pandemic</a>
|
||
</div></li>
|
||
<li><strong>Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters</strong> -
|
||
<div>
|
||
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant sparked concern due to its fast spread and the unprecedented number of mutations in the spike protein that enables it to partially evade spike-based COVID-19 vaccine-induced humoral immunity. In anticipation of a potential need for an Omicron spike-based vaccine, we generated an Ad26 vector encoding an Omicron (BA.1) spike protein (Ad26.COV2.S.529). Ad26.COV2.S.529 encodes for a prefusion stabilized spike protein, similar to the current COVID-19 vaccine Ad26.COV2.S encoding the Wuhan-Hu-1 spike protein. We verified that spike expression by Ad26.COV2.S.529 was comparable to Ad26.COV2.S. Immunogenicity of Ad26.COV2.S.529 was then evaluated in naive mice and SARS-CoV-2 Wuhan-Hu-1 spike pre-immunized hamsters. In naive mice, Ad26.COV2.S.529 elicited robust neutralizing antibodies against SARS-CoV-2 Omicron (BA.1) but not to SARS-CoV-2 Delta (B.1.617.2), while the opposite was observed for Ad26.COV2.S. In pre-immune hamsters, Ad26.COV2.S.529 vaccination resulted in robust increases in neutralizing antibody titers against both SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2), while Ad26.COV2.S vaccination only increased neutralizing antibody titers against the Delta variant. Our data imply that Ad26.COV2.S.529 can both expand and boost a Wuhan-Hu-1 spike-primed humoral immune response to protect against distant SARS-CoV-2 variants.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.03.04.482636v1" target="_blank">Immunogenicity of an Ad26-based SARS- CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters</a>
|
||
</div></li>
|
||
<li><strong>Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies Against Delta and Omicron in Mice</strong> -
|
||
<div>
|
||
As the existing vaccines do not completely prevent infections or community transmission of the coronavirus disease-19 (COVID-19), there is an unmet need for vaccines that can better combat severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants of concern (VOC) and also eliminate cold chain requirements. We show that highly thermo-tolerant monomeric and trimeric receptor binding domain derivatives that can withstand 100C for 90 minutes and 37C for four weeks elicit high antibody titres in mice that received prime-boost immunization on Days 0 and 21; and that these antibodies neutralize SARS-CoV-2 variants VIC31 (containing the Spike D614G mutation), Delta and Omicron (BA.1.1) VOC. Compared to VIC31, there was an average 14.4-fold reduction in neutralization against BA.1.1 for the three monomeric, and 16.5-fold re-duction for the three trimeric antigen-adjuvant combinations; the corresponding values against Delta were 2.5 and 3.0. Our findings suggest that monomeric formulations are suitable for the upcoming Phase I human clinical trials, and that there is potential for improving efficacy with vaccine matching to improve responses against emerging variants. These findings are consistent with in silico modelling and AlphaFold predictions which show that while oligomeric presentation can be generally beneficial, it can make important epitopes inaccessible.
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.biorxiv.org/content/10.1101/2022.03.03.481940v1" target="_blank">Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies Against Delta and Omicron in Mice</a>
|
||
</div></li>
|
||
<li><strong>Impact of Population Mixing Between a Vaccinated Majority and Unvaccinated Minority on Disease Dynamics. Implications for SARS-CoV-2</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
Background: The speed of vaccine development has been a singular achievement during the SARS-CoV-2 pandemic, though uptake has not been universal. Vaccine opponents often frame their opposition in terms of the rights of the unvaccinated. Our objective was to explore the impact of mixing of vaccinated and unvaccinated populations on risk among vaccinated individuals. Methods: We constructed a simple Susceptible-Infectious-Recovered (SIR) compartmental model of a respiratory infectious disease with two connected sub-populations: vaccinated individuals and unvaccinated individuals. We simulated a spectrum of patterns of mixing between vaccinated and unvaccinated groups that ranged from random mixing to like-with-like mixing (complete assortativity), where individuals preferentially have contact with others with the same vaccination status. We evaluated the dynamics of an epidemic within each subgroup, and in the population as a whole. Results: The relative risk of infection was markedly higher among unvaccinated individuals than among vaccinated individuals. However, the contact-adjusted contribution of unvaccinated individuals to infection risk during the epidemic was disproportionate, with unvaccinated individuals contributing to infections among the vaccinated at a rate higher than would have been expected based on contact numbers alone. As assortativity increased, attack rates among the vaccinated decreased, but the contact-adjusted contribution to risk among vaccinated individuals derived from contact with unvaccinated individuals increased. Interpretation: While risk associated with avoiding vaccination during a virulent pandemic accrues chiefly to the unvaccinated, the choices of unvaccinated individuals impact the health and safety of vaccinated individuals in a manner disproportionate to the fraction of unvaccinated individuals in the population.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.12.14.21267742v2" target="_blank">Impact of Population Mixing Between a Vaccinated Majority and Unvaccinated Minority on Disease Dynamics. Implications for SARS-CoV-2</a>
|
||
</div></li>
|
||
<li><strong>Modeling on Wastewater Treatment Process in Saudi Arabia: a perspective of Covid-19</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
The novel coronavirus disease (COVID-19) pandemic has had devastating effects on healthcare systems and the global economy. Moreover, coronavirus has been found in human feces, sewage, and in wastewater treatment plants. In this paper, we highlight the transmission behavior, occurrence, and persistence of the virus in sewage and wastewater treatment plants. Our approach follows the process of identifying a coronavirus hotspot through existing wastewater plants in major cities of Saudi Arabia. The mathematical distributions, including the log-normal distribution, Gaussian model, and susceptible exposed infected recovery (SEIR) model, are adopted to predict the coronavirus load in wastewater plants. We highlight not only the potential virus removal techniques from wastewater treatment plants, but also methods of tracing SARS-CoV-2 in humans through wastewater treatment plants.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html- link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2021.11.22.21266599v3" target="_blank">Modeling on Wastewater Treatment Process in Saudi Arabia: a perspective of Covid-19</a>
|
||
</div></li>
|
||
<li><strong>Identifying SARS-CoV-2 Variants of Concern through saliva-based RT-qPCR by targeting recurrent mutation sites</strong> -
|
||
<div>
|
||
<p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom">
|
||
SARS-CoV-2 variants of concern (VOCs) continue to pose a public health threat which necessitates a real-time monitoring strategy to compliment whole genome sequencing. Thus, we investigated the efficacy of competitive probe RT- qPCR assays for six mutation sites identified in SARS-CoV-2 VOCs and, after validating the assays with synthetic RNA, performed these assays on positive saliva samples. When compared with whole genome sequence results, the SΔ69-70 and ORF1aΔ3675-3677 assays demonstrated 93.60% and 68.00% accuracy, respectively. The SNP assays (K417T, E484K, E484Q, L452R) demonstrated 99.20%, 96.40%, 99.60%, and 96.80% accuracies, respectively. Lastly, we screened 345 positive saliva samples from December 7-22, 2021 using Omicron-specific mutation assays and were able to quickly identify rapid spread of Omicron in Upstate South Carolina. Our workflow demonstrates a novel approach for low-cost, real-time population screening of VOCs.
|
||
</p>
|
||
</div>
|
||
<div class="article-link article-html-link">
|
||
🖺 Full Text HTML: <a href="https://www.medrxiv.org/content/10.1101/2022.03.02.22271785v1" target="_blank">Identifying SARS-CoV-2 Variants of Concern through saliva-based RT-qPCR by targeting recurrent mutation sites</a>
|
||
</div></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-clinical-trials">From Clinical Trials</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>EPIC-Peds: Study of Oral PF-07321332 (Nirmatrelvir)/Ritonavir in Nonhospitalized COVID-19 Pediatric Patients at Risk for Severe Disease</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: nirmatrelvir; Drug: ritonavir<br/><b>Sponsor</b>: Pfizer<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Anti-inflammatory Drug Algorithm for COVID-19 Home Treatment</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: Recommended treatment schedule; Drug: Usual care<br/><b>Sponsors</b>: Mario Negri Institute for Pharmacological Research; Family physicians<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Transcranial Direct Stimulation for Persistent Fatigue Treatment Post-COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Device: Active tDCS; Device: Sham tDCS<br/><b>Sponsor</b>: Hospital San Carlos, Madrid<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID 19 in Adults in Mongolia- Mongolia, Indonesia, Australia Coronavirus (MIACoV).</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: Tozinameran - Standard Dose; Biological: Tozinameran - Fractional Dose<br/><b>Sponsors</b>: Murdoch Childrens Research Institute; Coalition for Epidemic Preparedness Innovations; PATH; The Peter Doherty Institute for Infection and Immunity<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Vale+ Tu Salud: Corner-Based Randomized Trial to Test a Latino Day Laborer Program Adapted to Prevent COVID 19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Behavioral: COVID-19 Group Problem Solving; Behavioral: Control Group-standard of care<br/><b>Sponsors</b>: The University of Texas Health Science Center, Houston; National Institute on Minority Health and Health Disparities (NIMHD)<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A Phase III, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TD0069 Capsule as a Combination Regimen With Standard Treatment for Patients With Mild to Moderate COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Drug: TD0069 hard capsule; Drug: TD0069 Placebo<br/><b>Sponsors</b>: Sao Thai Duong Joint Stock Company; Clinical Training Company<br/><b>Recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nebulised Heparin in Patients With COVID-19 Pneumonia</strong> - <b>Condition</b>: COVID-19 Pneumonia<br/><b>Intervention</b>: Drug: Unfractionated heparin<br/><b>Sponsor</b>: Lady Reading Hospital, Pakistan<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Nutrition and LOComotoric Rehabilitation in Long COVID-19</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Other: Intervention group<br/><b>Sponsors</b>: <br/>
|
||
Universitair Ziekenhuis Brussel; Vrije Universiteit Brussel<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults</strong> - <b>Condition</b>: COVID-19<br/><b>Intervention</b>: Biological: BBV152<br/><b>Sponsor</b>: Ocugen<br/><b>Active, not recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Reparixin as add-on Therapy to Standard of Care to Limit Disease Progression in Adult Patients With COVID-19.</strong> - <b>Conditions</b>: COVID-19 Pneumonia; Sars-CoV-2 Infection<br/><b>Interventions</b>: Drug: Reparixin; Other: Placebo<br/><b>Sponsor</b>: Dompé Farmaceutici S.p.A<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-COV-2 VIRUS (COVID-19).</strong> - <b>Conditions</b>: COVID-19; Upper Respiratory Tract Infections<br/><b>Intervention</b>: Device: TaffiX™<br/><b>Sponsor</b>: Nasus Pharma<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19</strong> - <b>Conditions</b>: COVID-19 Respiratory Infection; COVID-19 Pneumonia; Covid19<br/><b>Intervention</b>: <br/>
|
||
Drug: Pamrevlumab<br/><b>Sponsor</b>: Fondazione Policlinico Universitario Agostino Gemelli IRCCS<br/><b>Completed</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants</strong> - <b>Condition</b>: SARS-CoV-2<br/><b>Interventions</b>: Biological: CV2CoV (2 µg); Biological: CV2CoV (4 µg); Biological: CV2CoV (8 µg); Biological: CV2CoV (12 µg); Biological: CV2CoV (16 µg); Biological: CV2CoV (20 µg)<br/><b>Sponsors</b>: GlaxoSmithKline; CureVac AG<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong</strong> - <b>Condition</b>: COVID-19<br/><b>Interventions</b>: Biological: COVID-19 Vaccine (Vero Cell), Inactivated (Medium-dose); Biological: COVID-19 Vaccine (Vero Cell), Inactivated (High-dose)<br/><b>Sponsor</b>: <br/>
|
||
Sinovac Research and Development Co., Ltd.<br/><b>Not yet recruiting</b></p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>The Effect of Mobile Health Application Based on Omaha System on Symptoms and Quality of Life in COVID-19 Patients</strong> - <b>Conditions</b>: COVID-19; Symptoms and Signs; Quality of Life<br/><b>Interventions</b>: Other: COVOS app; Other: Standard Care<br/><b>Sponsors</b>: Kocaeli University; Istanbul University-Cerrahpasa; The Scientific and Technological Research Council of Turkey<br/><b>Not yet recruiting</b></p></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-pubmed">From PubMed</h1>
|
||
<ul>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Early reduction of SARS-CoV-2-replication in bronchial epithelium by kinin B(2) receptor antagonism</strong> - SARS-CoV-2 has evolved to enter the host via the ACE2 receptor which is part of the kinin-kallikrein pathway. This complex pathway is only poorly understood in context of immune regulation but critical to control infection. This study examines SARS-CoV-2-infection and epithelial mechanisms of the kinin-kallikrein-system at the kinin B(2) receptor level in SARS-CoV-2-infection that is of direct translational relevance. From acute SARS-CoV-2-positive study participants and -negative controls,…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Recombinant human interleukin-7 reverses T cell exhaustion ex vivo in critically ill COVID-19 patients</strong> - CONCLUSIONS: Severe COVID-19 patients present with features of profound T cell exhaustion upon ICU admission which can be reversed ex vivo by rhIL-7. These results reinforce our understanding of severe COVID-19 pathophysiology and opens novel therapeutic avenues to treat such critically ill patients based of immunomodulation approaches. Defining the appropriate timing for initiating such immune-adjuvant therapy in clinical setting and the pertinent markers for a careful selection of patients are…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Antiviral Effect of Selenomethionine on Porcine Deltacoronavirus in Pig Kidney Epithelial Cells</strong> - Porcine deltacoronavirus (PDCoV) is an emerging porcine intestinal coronavirus in recent years, which mainly causes different degrees of vomiting and diarrhea in piglets and has caused great harm to the swine husbandry worldwide since its report. Selenium is an essential trace element for organisms and has been demonstrated to have antiviral effects. In this study, pig kidney epithelial (LLC-PK) cells were used to study the antiviral activity of selenomethionine (Se-Met) (2, 4, 8, and 16 μM)…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Role of Dexamethasone and Methylprednisolone Corticosteroids in Coronavirus Disease 2019 Hospitalized Patients: A Review</strong> - The WHO announced coronavirus disease 2019 (COVID-19) as a pandemic disease globally on March 11, 2020, after it emerged in China. The emergence of COVID-19 has lasted over a year, and despite promising vaccine reports that have been produced, we still have a long way to go until such remedies are accessible to everyone. The immunomodulatory strategy has been kept at the top priority for the research agenda for COVID-19. Corticosteroids have been used to modulate the immune response in a wide…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Evaluation of a commercial ELISA as alternative to plaque reduction neutralization test to detect neutralizing antibodies against SARS-CoV-2</strong> - High-throughput detection of neutralizing antibodies against SARS-CoV-2 presents a valuable tool for vaccine trials or investigations of population immunity. We evaluate the performance of the first commercial surrogate virus neutralization test (sVNT, GenScript Biotech) against SARS-CoV-2 plaque reduction neutralization test (PRNT) in convalescent and vaccinated individuals. We compare it to five other ELISAs, two of which are designed to detect neutralizing antibodies. In 491 pre-vaccination…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Association between FIASMA psychotropic medications and reduced risk of intubation or death in individuals with psychiatric disorders hospitalized for severe COVID-19: an observational multicenter study</strong> - The acid sphingomyelinase (ASM)/ceramide system may provide a useful framework for better understanding SARS-CoV-2 infection and the repurposing of psychotropic medications functionally inhibiting the acid sphingomyelinase/ceramide system (named FIASMA psychotropic medications) against COVID-19. We examined the potential usefulness of FIASMA psychotropic medications in patients with psychiatric disorders hospitalized for severe COVID-19, in an observational multicenter study conducted at Greater…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Network pharmacology-based predictions of active components and pharmacological mechanisms of Artemisia annua L. for the treatment of the novel Corona virus disease 2019 (COVID-19)</strong> - CONCLUSIONS: These findings suggest that A. annua may prevent and inhibit the inflammatory processes related to COVID-19.</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>HDAC inhibition as neuroprotection in COVID-19 infection</strong> - The SARS-CoV-2 virus is responsible of COVID-19 affecting millions of humans around the world. COVID-19 shows diverse clinical symptoms (fever, cough, fatigue, diarrhea, body aches, headaches, anosmia and hyposmia). Approximately 30% of the patients with COVID-19 showed neurological symptoms, these going from mild to severe manifestations including headache, dizziness, impaired consciousness, encephalopathy, anosmia, hypogeusia, hyposmia, psychology and psychiatry among others. The neurotropism…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Trace element homeostasis in the neurological system after SARS-CoV-2 infection: Insight into potential biochemical mechanisms</strong> - CONCLUSION: Trace elements play important roles in viral infections, such as helping to activate immune cells, produce antibodies, and inhibit virus replication. However, the relationship between trace elements and virus infections is complex since the specific functions of several elements remain largely undefined. Therefore, there is still a lot to be explored to understand the biochemical mechanisms involved between trace elements and viral infections, especially in the brain.</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>In silico analysis highlighting the prevalence of BCL2L1 gene and its correlation to miRNA in human coronavirus (HCoV) genetic makeup</strong> - The ongoing pandemic that resulted from coronavirus disease (COVID-19), which is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), had been spiraling out of control with no known antiviral drugs or vaccines. Due to the extremely serious nature of the disease, it has claimed many lives, with a mortality rate of 3.4% declared by the World Health Organization (WHO) on March 3, 2020. The aim of this study is to gain an understanding of the regulatory nature of the proteins…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Anti-inflammatory and anti-viral actions of anionic pulmonary surfactant phospholipids</strong> - Pulmonary surfactant is a mixture of lipids and proteins, consisting of 90% phospholipid, and 10% protein by weight, found predominantly in pulmonary alveoli of vertebrate lungs. Two minor components of pulmonary surfactant phospholipids, phosphatidylglycerol (PG) and phosphatidylinositol (PI), are present within the alveoli at very high concentrations, and exert anti-inflammatory effects by regulating multiple Toll like receptors (TLR2/1, TLR4, and TLR2/6) by antagonizing cognate…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concern</strong> - COVID-19, an infectious disease caused by the SARS-CoV-2 virus, emerged globally in early 2020 and has remained a serious public health issue. To date, although several preventative vaccines have been approved by FDA and EMA, vaccinated individuals increasingly suffer from breakthrough infections. Therapeutic antibodies may provide an alternative strategy to neutralize viral infection and treat serious cases; however, the clinical data and our experiments show that some FDA-approved monoclonal…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Rapid and Quantitative In Vitro Evaluation of SARS-CoV-2 Neutralizing Antibodies and Nanobodies</strong> - Neutralizing monoclonal antibodies and nanobodies have shown promising results as potential therapeutic agents for COVID-19. Identifying such antibodies and nanobodies requires evaluating the neutralization activity of a large number of lead molecules via biological assays, such as the virus neutralization test (VNT). These assays are typically time- consuming and demanding on-lab facilities. Here, we present a rapid and quantitative assay that evaluates the neutralizing efficacy of an antibody…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Complement Activation via the Lectin and Alternative Pathway in Patients With Severe COVID-19</strong> - Complement plays an important role in the direct defense to pathogens, but can also activate immune cells and the release of pro-inflammatory cytokines. However, in critically ill patients with COVID-19 the immune system is inadequately activated leading to severe acute respiratory syndrome (SARS) and acute kidney injury, which is associated with higher mortality. Therefore, we characterized local complement deposition as a sign of activation in both lungs and kidneys from patients with severe…</p></li>
|
||
<li data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>Modulation of Innate Antiviral Immune Response by Porcine Enteric Coronavirus</strong> - Host’s innate immunity is the front-line defense against viral infections, but some viruses have evolved multiple strategies for evasion of antiviral innate immunity. The porcine enteric coronaviruses (PECs) consist of porcine epidemic diarrhea virus (PEDV), porcine deltacoronavirus (PDCoV), transmissible gastroenteritis coronavirus (TGEV), and swine acute diarrhea syndrome-coronavirus (SADS-CoV), which cause lethal diarrhea in neonatal pigs and threaten the swine industry worldwide. PECs…</p></li>
|
||
</ul>
|
||
<h1 data-aos="fade-right" id="from-patent-search">From Patent Search</h1>
|
||
<ul>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>METHOD AND SYSTEM FOR IMPLEMENTING IMPROVED GENERALIZED FUZZY PEER GROUP WITH MODIFIED TRILATERAL FILTER TO REMOVE MIXED IMPULSE AND ADAPTIVE WHITE GAUSSIAN NOISE FROM COLOR IMAGES</strong> - ABSTRACTMETHOD AND SYSTEM FOR IMPLEMENTING IMPROVED GENERALIZED FUZZY PEER GROUP WITH MODIFIED TRILATERAL FILTER TO REMOVE MIXED IMPULSE AND ADAPTIVE WHITE GAUSSIAN NOISE FROM COLOR IMAGESThe present invention provides a new approach is proposed that includes fuzzy-based approach and similarity function for filtering the mixed noise. In a peer group, the similarity function was adaptive to edge information and local noise level, which was utilized for detecting the similarity among pixels. In addition, a new filtering method Modified Trilateral Filter (MTF) with Improved Generalized Fuzzy Peer Group (IGFPG) is proposed to remove mixed impulse and Adaptive White Gaussian Noise from Color Images. The modified trilateral filter includes Kikuchi algorithm and loopy belief propagation to solve the inference issues on the basis of passing local message. In this research work, the images were collected from KODAK dataset and a few real time multimedia images like Lena were also used for testing the effectiveness of the proposed methodology. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN351884428">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A STUDY ON MENTAL HEALTH, STRESS AND ANXIETY AMONG COLLEGE STUDENTS DURING COVID-19</strong> - SARS-Cov-2 virus causes an infectious disease coronavirus(COVID-19).The Students life is made harder by COVID-19.The human reaction that happens normally to everyone through physical or emotional tension is stress. Feeling of angry, nervous and frustration caused through any thought or events leads to stress. As college closures and cancelled events, students are missing out on some of the biggest moments of their young lives as well as everyday moments like chatting with friend, participating in class and cultural programme. For students facing life changes due to the outbreak are feeling anxious, isolated and disappointed which lead them to feel all alone. We like to take the help of expert adolescent psychologist to find out the techniques to practice self-care and look after their mental health. We would like to find out whether techniques used reduce the anxiety and stress among Engineering Students. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN351884923">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A METHOD FOR THE TREATMENT OF COVID-19 INFECTIONS WITH PALMITOYLETHANOLAMIDE</strong> - - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=AU351870997">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>A CENTRAL TRANSACTION AUTHENTIC SYSTEM FOR OTP VERIFICATION</strong> - The present invention relates to a central transaction authentic system (100) for OTP verification. The system (100) comprises one or more user display units (102), one or more financial units (104), an account deposit unit (106), an OTP authentication unit (108) and a service server unit (110). The central transaction authentic system (100) for OTP verification work as Anti-money laundering measure. The system (100) also helpful for minimizing rate of cybercrime. The central transaction authentic system (100) for OTP verification that can neutralize digital financial fraud. The present invention provides a central transaction authentic system (100) for OTP verification that can monitor and analyze every transaction and customer interaction across its customer base for suspicious and potentially criminal activity. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN350377210">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>FORMULATIONS AND METHOD FOR PREPARATION OF HERBAL MEDICATED TRANSPARENT SOAP</strong> - ABSTRACTFORMULATIONS AND METHOD FOR PREPARATION OF HERBAL MEDICATED TRANSPARENT SOAPThe present invention provides formulations for herbal medicated transparent soaps and method of preparation of the same. Transparent soaps are prepared by saponification of mixture of non-edible oils to get the desired consistency and cleaning action. Nonvolatile alcohols and other transparency promoters are used to get good transparency and binding properties. Herbal extracts of different herbs are added to get medicated properties. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN350377796">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>SOCIAL NAVIGATION SYSTEM FOR MOBILE ROBOTS IN THE EMERGENCY DEPARTMENT TECHNOLOGY</strong> - The emergency department (ED) is a safety-critical environment in which healthcare workers (HCWs) are overburdened, overworked, and have limited resources, especially during the COVID-19 pandemic. One way to address this problem is to explore the use of robots that can support clinical teams, e.g., to deliver materials or restock supplies. However, due to EDs being overcrowded, and the cognitive overload HCWs experience, robots need to understand various levels of patient acuity so they avoid disrupting care delivery. In this invention, we introduce the Safety-Critical Deep Q-Network (SafeDQN) system, a new acuity-aware navigation system for mobile robots. SafeDQN is based on two insights about care in EDs: high-acuity patients tend to have more HCWs in attendance and those HCWs tend to move more quickly. We compared SafeDQN to three classic navigation methods, and show that it generates the safest, quickest path for mobile robots when navigating in a simulated ED environment. We hope this work encourages future exploration of social robots that work in safety-critical, human-centered environments, and ultimately help to improve patient outcomes and save lives. Figure 1. - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=IN349443355">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种新型冠状病毒核酸检测试剂盒</strong> - 本发明公开了一种新型冠状病毒核酸检测试剂盒，属于生物检测技术领域。本发明使用实时荧光定量交叉引物等温扩增技术检测新型冠状病毒，设计了两组适用于这一技术的引物。两组引物分别针对型冠状病毒基因组中的ORF1ab基因和型冠状病毒基因组中的S基因进行检测。本发明新型冠状病毒核酸检测试剂盒特异性强，灵敏度高，不仅可以对样品进行定性定量的检测，还可以实时观测数据的变化，有利于对样品数据的全面收集，方便进行下一步的研究。因此本发明不仅适用于现场快速检测，还适用于以科研为目的的检测。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN351915848">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种新型冠状病毒核酸纯化试剂及纯化方法</strong> - 本发明公开了一种新型冠状病毒核酸纯化试剂及纯化方法，属于核酸纯化技术领域，核酸纯化试剂包括包覆有硒代赖氨酸改性壳聚糖的纳米磁珠、结合液、洗涤I液、洗涤II液和洗脱液。纯化方法包括，将待纯化样本、磁珠和结合液加入离心管中，混匀，磁分离，弃上清；将离心管中加入洗涤I液，清洗，磁分离，吸净管盖及管底的残液；将离心管中加入洗涤II液，清洗，磁分离，吸净管盖及管底的残液；将离心管中加入洗脱液，60‑70℃下放置10‑15min，每隔1‑2min轻摇混匀，磁分离，小心吸取上清液至新的离心管中，放入‑20℃冰箱保存。本发明方法纯化过程快速、结果准确、精密度高，能够提高核酸纯化的产量、纯度、重复性和稳定性。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN351915839">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种全人源抗新冠病毒广谱中和抗体ZW2G10及应用</strong> - 本发明公开了一种抗SARS‑CoV‑2的全人源单克隆抗体ZW2G10，所述抗体具有独特的CDR分区，其抗原识别表位位于S1蛋白的RBD区。所述抗体中和新冠病毒野生型、Alpha、Beta、Gamma、Delta和Omicron变异株假病毒的EC50分别是14.19、14.12、18.41、15.59、36.18、19.26ng/mL。ZW2G10对目前的主要变异株具有广谱高效中和活性。本发明公开的单克隆抗体还具有高表达、全人源、稳定性好的特点，适合产业化生产，对于应对新冠变异株导致的爆发流行具有重大应用价值。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN351915789">link</a></p></li>
|
||
<li><p data-aos="fade-left" data-aos-anchor-placement="bottom-bottom"><strong>一种抗新冠病毒全人源广谱中和抗体ZWC12及应用</strong> - 本发明公开了一种抗SARS‑CoV‑2的全人源单克隆抗体ZWC12，所述抗体具有独特的CDR分区，其抗原识别表位位于S1蛋白的RBD区。所述抗体中和新冠病毒野生型、Alpha、Beta、Gamma、Delta、Omicron变异株假病毒的EC50分别是1.041、0.124、0.162、0.136、0.411、0.093μg/mL，该抗体对目前主要变异株具有广谱高效中和活性。所述抗体还具有高表达、全人源、稳定性好的特点，适合产业化生产，对于应对新冠变异株导致的爆发流行具有重要应用价值。 - <a href="https://patentscope.wipo.int/search/en/detail.jsf?docId=CN351925790">link</a></p></li>
|
||
</ul>
|
||
|
||
|
||
<script>AOS.init();</script></body></html> |